NCT02182258View on ClinicalTrials.gov

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Conditions
Healthy
Interventions
DRUG

BIBF 1120 soft gelatine capsule

DRUG

BIBF 1120 intravenous solution

DRUG

Placebo ampoule

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02182258 - Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects | Biotech Hunter | Biotech Hunter